Business Description
Tonghua Dongbao Pharmaceutical Co Ltd
NAICS : 325412
ISIN : CNE000000H87
Share Class Description:
SHSE:600867: Class ACompare
Compare
Traded in other countries / regions
600867.China Index Membership
SSE Composite IndexCSI 500 IndexCSI 300 IndexCSI 300 Index IPO Date
1994-08-24Description
Tonghua Dongbao Pharmaceutical Co Ltd is a China-based firm. Its engaged in the production and distribution of pharmaceutical products. Its products include human insulin injection, Heart and brain capsule, Vitamin e soft capsule, and Oral detoxification products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.76 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 1.28 | |||||
| Interest Coverage | 40.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 14.01 | |||||
| Beneish M-Score | -3.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.8 | |||||
| 3-Year EBITDA Growth Rate | 7.7 | |||||
| 3-Year EPS without NRI Growth Rate | 7.9 | |||||
| 3-Year FCF Growth Rate | -9.8 | |||||
| 3-Year Book Growth Rate | 9.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.72 | |||||
| 9-Day RSI | 47.3 | |||||
| 14-Day RSI | 45.53 | |||||
| 3-1 Month Momentum % | -7.68 | |||||
| 6-1 Month Momentum % | 1.05 | |||||
| 12-1 Month Momentum % | -26.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | |||||
| Quick Ratio | 2.6 | |||||
| Cash Ratio | 0.82 | |||||
| Days Inventory | 497.27 | |||||
| Days Sales Outstanding | 104.68 | |||||
| Days Payable | 77.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.34 | |||||
| Dividend Payout Ratio | 1.21 | |||||
| 3-Year Dividend Growth Rate | 7.7 | |||||
| Forward Dividend Yield % | 3.34 | |||||
| 5-Year Yield-on-Cost % | 6.86 | |||||
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | 2 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.83 | |||||
| Operating Margin % | 23.27 | |||||
| Net Margin % | 14.04 | |||||
| FCF Margin % | 3.06 | |||||
| ROE % | 4.96 | |||||
| ROA % | 4.61 | |||||
| ROIC % | 8.08 | |||||
| 3-Year ROIIC % | 11.27 | |||||
| ROC (Joel Greenblatt) % | 9.69 | |||||
| ROCE % | 5.53 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 41.78 | |||||
| Forward PE Ratio | 20.04 | |||||
| PE Ratio without NRI | 36.33 | |||||
| Shiller PE Ratio | 15.67 | |||||
| PEG Ratio | 3.33 | |||||
| PS Ratio | 6.48 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 3.01 | |||||
| Price-to-Free-Cash-Flow | 140.57 | |||||
| Price-to-Operating-Cash-Flow | 24.51 | |||||
| EV-to-EBIT | 38.92 | |||||
| EV-to-Forward-EBIT | 17.05 | |||||
| EV-to-EBITDA | 38.92 | |||||
| EV-to-Forward-EBITDA | 15.14 | |||||
| EV-to-Revenue | 6.18 | |||||
| EV-to-Forward-Revenue | 6.16 | |||||
| EV-to-FCF | 197.5 | |||||
| Price-to-GF-Value | 1.41 | |||||
| Price-to-Projected-FCF | 2.21 | |||||
| Price-to-DCF (Earnings Based) | 1.56 | |||||
| Price-to-DCF (FCF Based) | 5.61 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Graham-Number | 2.21 | |||||
| Price-to-Net-Current-Asset-Value | 11.75 | |||||
| Earnings Yield (Greenblatt) % | 2.57 | |||||
| FCF Yield % | 0.51 | |||||
| Forward Rate of Return (Yacktman) % | -1.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tonghua Dongbao Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,431.642 | ||
| EPS (TTM) (Â¥) | 0.18 | ||
| Beta | 0.76 | ||
| 3-Year Sharpe Ratio | -0.46 | ||
| 3-Year Sortino Ratio | -0.64 | ||
| Volatility % | 16.1 | ||
| 14-Day RSI | 45.53 | ||
| 14-Day ATR (Â¥) | 0.151102 | ||
| 20-Day SMA (Â¥) | 7.679 | ||
| 12-1 Month Momentum % | -26.48 | ||
| 52-Week Range (Â¥) | 7.02 - 11.09 | ||
| Shares Outstanding (Mil) | 1,958.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tonghua Dongbao Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tonghua Dongbao Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tonghua Dongbao Pharmaceutical Co Ltd Frequently Asked Questions
What is Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867)'s stock price today?
The current price of SHSE:600867 is ¥7.52. The 52 week high of SHSE:600867 is ¥11.09 and 52 week low is ¥7.02.
When is next earnings date of Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867)?
The next earnings date of Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867) is .
Does Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867) pay dividends? If so, how much?
The Dividend Yield %  of Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867) is 3.34% (As of Today), Highest Dividend Payout Ratio of Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867) was 1.31. The lowest was 0.34. And the median was 0.43. The  Forward Dividend Yield % of Tonghua Dongbao Pharmaceutical Co Ltd(SHSE:600867) is 3.34%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers